XAIRA
Pending · Under Examination LIVE/APPLICATION/Under Examination
What this record means
The record shows that the mark “XAIRA” is still pending on the Principal Register and is owned by XAIRA THERAPEUTICS, INC., a Delaware corporation. The application covers pharmaceuticals and scientific & technology services, specifically pharmaceutical therapeutics for immune‑mediated inflammatory diseases and related conditions, and research and development services that use artificial intelligence and machine learning in the pharmaceutical field. A similar name would raise the closest concern in these areas of drug development and medical treatment. The record does not give the owner control over every use of the word “XAIRA”; it only applies to the goods and services listed. The most recent event is the approval of a second extension to file a Statement of Use on July 3 2026, and no enforcement actions are visible in the supplied history. For anyone thinking of a similar name, the pending status and the specific pharmaceutical and research services listed suggest a meaningful risk of conflict in those fields.
Informational only - not legal advice.Mark Trademark, Service Mark
| Drawing type | 4 - STANDARD CHARACTER MARK |
| Filing basis | Intent-to-Use (§1(b)). |
| Status | A second request for extension of time to file a Statement of Use has been granted. |
Key dates
| Application filed | Mar 29, 2024 |
| Published for opposition | May 13, 2025 |
| Notice of Allowance | Jul 08, 2025 |
| Status date | Jul 03, 2026 |
Goods & services
Pharmaceutical therapeutics and medical therapeutics for treating indications and co-morbidities underlying immune-mediated inflammatory diseases, namely, pharmaceutical preparations for treating immunological diseases, cardiometabolic diseases, infectious diseases, and oncological diseases
Pharmaceutical research and development services using artificial intelligence and machine learning; Scientific and medical research in the field of pharmaceutical development using artificial intelligence and machine learning; Research and development of technology in the field of pharmaceuticals; Development of pharmaceutical medicines; Drug development and discovery
Owner & representation
| Owner | XAIRA THERAPEUTICS, INC. |
| Address | 601 CALIFORNIA STREET, 6TH FLOOR, SAN FRANCISCO, CALIFORNIA UNITED STATES 94108 |
| Entity | CORPORATION - organized in DELAWARE |
| Attorney of record | Mark A. Jansen |
| Correspondent | Mark A. Jansen |
| Attorney email | t********@*****.com |
| Correspondent email | t********@*****.com |
| Correspondent phone | 6********0 |
| Correspondent address | Mountain View, CALIFORNIA |